Know Cancer

or
forgot password

Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma


Phase 2
18 Years
80 Years
Not Enrolling
Both
Renal Cell Carcinoma

Thank you

Trial Information

Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma


Patients with high-risk RCC have a dismal prognosis. To date, no effective adjuvant therapy
exists for this patients category. We suggest that combination of granulocyte-macrophage
colony-stimulating factor (GM-CSF), interferon alpha (IFN) and interleukin-2 (IL-2)
stimulate immune system from dendritic cells till cytotoxic T-lymphocytes step by step and
eliminate residuary tumor cells.

This prospective, non-randomized, phase II trial assessed low-dose GM-CSF, IFN and IL-2
postoperatively in patients with high-risk renal cell carcinoma.


Inclusion Criteria:



- completely resected advanced high-risk RCC

- T3b-c, T4, or N1-2, or M1 disease resected to no evidence of disease (AJCC-TNM, 2002)
Patients must have recovered from any effects of surgery, which must have been -
excellent performance status (Eastern Cooperative Oncology Group performance status
of 0 or 1);

- adequate organ function defined as WBC count 4,000/µL, platelet count 100,000/µL,
hemoglobin 10 g/dL, serum creatinine 1.5 mg/dL or creatinine clearance 60 mL/min, and
direct bilirubin 1.5 mg/dL; and forced expiratory volume at 1 second more than 2.0 L
or 75% of predicted for height and age from pre-enrollment pulmonary function testing

- age 18 years and older

Exclusion Criteria:

- history or evidence of cardiac disease on ECG or autoimmunity

- prior systemic treatment for RCC

- history of invasive malignancy in the past 5 years or human immunodeficiency virus
positivity

- positive pregnancy test

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Disease-free survival (DFS)

Outcome Time Frame:

3.5 years

Safety Issue:

No

Principal Investigator

Lev Demidov, M.D., D.Sc.

Investigator Role:

Principal Investigator

Investigator Affiliation:

N.N. Blokhin Russian Cancer Research Center

Authority:

Russia: Ministry of Health of the Russian Federation

Study ID:

U1111-1114-6557

NCT ID:

NCT01176552

Start Date:

May 2004

Completion Date:

May 2010

Related Keywords:

  • Renal Cell Carcinoma
  • Kidney Cancer
  • Renal cell carcinoma
  • High risk
  • Adjuvant therapy
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location